Trikafta 100 mg (Elexacaftor GRANULES) 100 MG

TRIKAFTA 100 MG granules contain elexacaftor, a medication used to manage certain conditions. This oral treatment is designed for specific therapeutic uses and is manufactured by Vertex Pharmaceuticals in Canada.

Strength

100 MG

Manufacturer / TM Owner

VERTEX PHARMACEUTICALS (CANADA) INCORPORATED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TRIKAFTA 100 MG granules are primarily used to manage conditions related to cystic fibrosis. Elexacaftor, the active ingredient, works to improve the function of a protein involved in this condition. This medication is part of a broader treatment plan for individuals with specific genetic mutations.

Side Effects

Common effects of TRIKAFTA 100 MG granules may include improvements in respiratory function and overall well-being. Some users might experience mild gastrointestinal discomfort or other transient effects. Individual responses can vary, and it's important to monitor any changes while using this medication.

Precautions & Warnings

TRIKAFTA 100 MG granules should be handled with care, ensuring proper storage and administration as directed. It is essential to follow the guidance of a healthcare provider regarding its use, especially for individuals with pre-existing conditions or those taking other medications.

Avoid Interactions

TRIKAFTA 100 MG granules may interact with certain medications, including those metabolized by the liver's cytochrome P450 system. It is advisable to consult a healthcare provider before combining this medication with other treatments, particularly those known to affect liver enzymes.

Frequently Asked Questions

TRIKAFTA 100 MG granules are used to manage conditions related to cystic fibrosis, specifically in individuals with certain genetic mutations.

TRIKAFTA 100 MG granules are taken orally, typically mixed with a small amount of soft food or liquid. Follow the specific instructions provided by your healthcare provider.

Common effects may include improvements in respiratory function and mild gastrointestinal discomfort. Individual responses can vary.

TRIKAFTA 100 MG may interact with certain medications, so it's important to consult a healthcare provider before combining it with other treatments.

TRIKAFTA 100 MG granules are manufactured by Vertex Pharmaceuticals in Canada.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.